These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35398240)

  • 1. IL-3 signalling in the tumour microenvironment shapes the immune response via tumour endothelial cell-derived extracellular vesicles.
    Lopatina T; Koni M; Grange C; Cedrino M; Femminò S; Lombardo G; Favaro E; Brizzi MF
    Pharmacol Res; 2022 May; 179():106206. PubMed ID: 35398240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming.
    Lopatina T; Grange C; Cavallari C; Navarro-Tableros V; Lombardo G; Rosso A; Cedrino M; Pomatto MAC; Koni M; Veneziano F; Castellano I; Camussi G; Brizzi MF
    Oncogenesis; 2020 Oct; 9(10):90. PubMed ID: 33040091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway.
    Lombardo G; Gili M; Grange C; Cavallari C; Dentelli P; Togliatto G; Taverna D; Camussi G; Brizzi MF
    Oncogene; 2018 Mar; 37(9):1175-1191. PubMed ID: 29238040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating extracellular vesicles derived from tumor endothelial cells hijack the local and systemic anti-tumor immune response: Role of mTOR/G-CSF pathway.
    Koni M; Lopatina T; Grange C; Sarcinella A; Cedrino M; Bruno S; Buffolo F; Femminò S; Camussi G; Brizzi MF
    Pharmacol Res; 2023 Sep; 195():106871. PubMed ID: 37506784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
    Zhou Y; Yamamoto Y; Takeshita F; Yamamoto T; Xiao Z; Ochiya T
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated Stat5 trafficking Via Endothelial Cell-derived Extracellular Vesicles Controls IL-3 Pro-angiogenic Paracrine Action.
    Lombardo G; Dentelli P; Togliatto G; Rosso A; Gili M; Gallo S; Deregibus MC; Camussi G; Brizzi MF
    Sci Rep; 2016 May; 6():25689. PubMed ID: 27157262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular Vesicles Released by Tumor Endothelial Cells Spread Immunosuppressive and Transforming Signals Through Various Recipient Cells.
    Lopatina T; Favaro E; Danilova L; Fertig EJ; Favorov AV; Kagohara LT; Martone T; Bussolati B; Romagnoli R; Albera R; Pecorari G; Brizzi MF; Camussi G; Gaykalova DA
    Front Cell Dev Biol; 2020; 8():698. PubMed ID: 33015029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell-derived LC3B
    Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
    Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
    Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
    Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models.
    Yati S; Silathapanasakul A; Thakaeng C; Chanasakulniyom M; Songtawee N; Porntadavity S; Pothacharoen P; Pruksakorn D; Kongtawelert P; Yenchitsomanus PT; Chanmee T
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies.
    Liu J; Peng X; Yang S; Li X; Huang M; Wei S; Zhang S; He G; Zheng H; Fan Q; Yang L; Li H
    Cell Commun Signal; 2022 Jan; 20(1):14. PubMed ID: 35090497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
    Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer.
    Liang Y; Liu Y; Zhang Q; Zhang H; Du J
    Transl Res; 2021 May; 231():102-112. PubMed ID: 33321257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.